BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 10203264)

  • 1. A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer.
    Crown J
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):5-9. PubMed ID: 10203264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.
    Nabholtz JM; Crown J
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):4-9. PubMed ID: 9865685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
    Sparano JA
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):10-5. PubMed ID: 9865686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer.
    Ravdin PM
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-18-S10-21. PubMed ID: 9275002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution in the treatment of advanced breast cancer.
    Crown J
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):12-7. PubMed ID: 9865706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel (Taxotere) in combination: a step forward.
    Burris HA; Fields S; Peacock N
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
    van Oosterom AT
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting.
    Nabholtz JM; Tonkin K; Smylie M; Mackey J; Janowska-Wieczorek A
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):10-6. PubMed ID: 10203265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group.
    Aapro M
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):7-11. PubMed ID: 9865705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future perspectives of docetaxel (Taxotere) in front-line therapy.
    Piccart MJ; Di Leo A
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-27-S10-33. PubMed ID: 9275004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxoids: effective agents in anthracycline-resistant breast cancer.
    Ravdin PM
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):29-34. PubMed ID: 8604450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings.
    Aapro MS
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):17-21. PubMed ID: 10203266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recently initiated studies: neoadjuvant treatments in the next century.
    Gradishar WJ
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):26-9. PubMed ID: 10203268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel in combination chemotherapy for metastatic breast cancer.
    Khayat D; Antoine E
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
    Nabholtz JM; Thuerlimann B; Bezwoda WR; Melnychuk D; DeschĂȘnes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Aapro MS; Alaki M; Murawsky M; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel and docetaxel in breast and ovarian cancer.
    Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination.
    Bissery MC; Vrignaud P; Lavelle F
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):3-16. PubMed ID: 8604451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects.
    D'Andrea GM; Seidman AD
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-27-S13-44. PubMed ID: 9335514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Taxoids in combination chemotherapy for metastatic breast cancer.
    Dieras V; Fumoleau P; Bourgeois H; Misset JL; Azli N; Pouillart P
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():47-52. PubMed ID: 8862712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer.
    Harper P
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-30-S14-32. PubMed ID: 9335522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.